Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib and Retifanlimab in Advanced Dedifferentiated Liposarcoma
NCT06389799Phase 2Recruiting
- Sponsor
- Skåne University Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of pemigatinib, retifanlimab in dedifferentiated liposarcoma (DDL), sponsored by Skåne University Hospital. Started Jun 2024; status: recruiting.
02
Drugs
pemigatinibretifanlimab
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT06389799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389799.